Research Papers:
AMF/PGI-mediated tumorigenesis through MAPK-ERK signaling in endometrial carcinoma
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 2878 views | HTML 2860 views | ?
Abstract
Yiran Li1, Yuanhui Jia2, Qi Che2, Qian Zhou2, Kai Wang2, Xiao-Ping Wan3
1Department of Obstetrics and Gynecology, Shanghai First People's Hospital Affiliated to Shanghai Jiao Tong University, Shanghai, China
2Clinical and Translational Research Center, Shanghai First Maternity and Infant Hospital, Tongji University School of Medicine, Shanghai, China
3Department of Gynecology, Shanghai First Maternity and Infant Hospital, Tongji University School of Medicine, Shanghai, China
Correspondence to:
Kai Wang, e-mail: [email protected]
Xiao-Ping Wan, e-mail: [email protected]
Keywords: endometrial carcinoma, Autocrine Motility Factor (AMF)/PhosphoGlucose Isomerase (PGI), MAPK signaling pathway, invasion, prognosis
Received: April 29, 2015 Accepted: July 08, 2015 Published: July 20, 2015
ABSTRACT
Autocrine motility factor (AMF), which is also known as phosphoglucose isomerase (PGI), enhances tumor cell growth and motility. In this study, we found that AMF and its receptor were both highly expressed in Endometrial Carcinoma (EC) tissues compared to normal tissues. Levels of AMF were increased in serum of endometrial cancer patients. Downregulation of AMF by shRNA inhibited invasion, migration and proliferation as well as growth in a three-dimensional culture. AMF cytokine function, but not enzymatic activity of PGI, regulated tumorigenic activities of AMF. The MAPK-ERK1/2 pathway contributed to AMF-induced effects in EC cells. In agreement, Mek inhibitor decreased AMF-induced invasion, migration and proliferation of EC cells. In addition, in two mouse tumor metastasis models (EC cells delivered through left ventricle or intraperitoneally) AMF-silenced EC cells showed decreased tumor proliferative and metastatic capacities. We suggest that AMF/PGI is a potential therapeutic target in endometrial carcinoma.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 4708